With this in mind, a GSK3β inhibitor alone may not be appropriate for treating MFS—instead, combining GSK3β inhibitors with other drugs, all at lower concentrations, would allow us to target multiple signaling abnormalities while still being well tolerated by patients. Here, GSK3B is linked to Marfan syndrome.